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ABSTRACT
Eight commercially available tests for Mycoplasma
pneumoniae (Serodia-Myco II, Labsystems IgM
and IgG EIA, IgM and IgG LISA tests, Immuno-
Well IgG test and SeroMP IgM and IgG) were
compared using 204 single sera from healthy
individuals. IgM peaked in late childhood and
then declined, while IgG rose progressively into
adulthood. Inter-assay agreement was poor.
Positivity in Serodia-Myco II and LISA IgG was
associated with blood group or Coombs positiv-
ity, suggesting non-speciﬁc reactions. The study
conﬁrmed that single serum serology is unsuita-
ble for the diagnosis of M. pneumoniae infection,
and that commercially available tests need further
improvement.
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Mycoplasma pneumoniae is one of the most com-
mon causes of pneumonia [1], but culture of
M. pneumoniae is performed rarely because of the
lengthy growth period and low yield [2,3]. Other
diagnostic modalities, such as PCR, are available,
but many protocols are in use and standardisation
is lacking [4]; commercial molecular diagnostic
kits have not yet been properly evaluated. For
many decades, conﬁrmation of M. pneumoniae
infection has been based on serological tests.
The reference method, i.e., the complement
ﬁxation assay, is time-consuming and technically
demanding [5]. Moreover, some reports have
suggested that M. pneumoniae infection is not
recognised in a proportion of patients, even if
paired acute and convalescent sera are examined
[3,5,6]. A range of commercially available sero-
logical kits has replaced the complement ﬁxation
test in most laboratories [2,7]; however, for most
patients, only one serum sample is available.
Indeed, most kits include a deﬁnition for acute
infection using a single serum sample. Previous
studies have evaluated commercially available
kits using either positive paired sera or sera from
patients with a positive nucleic acid ampliﬁcation
result by PCR or nucleic acid sequence-based
ampliﬁcation [6,8–10]. One study from France [8]
suggested that positive IgM and IgG results
varied according to the kit used and the age of
the patient. Another compared serological assays
in blood donors, but did not compare the tests in
relation to age or other potentially signiﬁcant
variables [11]. Data concerning the performance
of these assays in healthy populations are scarce.
Therefore, the present study compared the fre-
quency and age associations of positive single test
results obtained using several commercially avail-
able serological kits for healthy individuals.
Sera were drawn from samples scheduled for
disposal at the Hadassah Hospital blood bank
(Jerusalem, Israel) during the period January–June
2004. The sera had been obtained either from blood
bank donors (aged ‡ 18 years) or from patients
admitted for elective surgical procedures (patients
aged 0–18 years). The study was approved by the
institutional ethics committee. Data available
included age, gender, blood type and auto-anti-
bodies against erythrocytes. At least 20 samples
were collected in the age groups 0–0.5, 0.6–2, 3–6,
7–12, 13–18, 19–26, 27–40, 41–65 and > 65 years. A
few sera were discarded because of bacterial
contamination, small volume or turbidity, leaving
a total of 204 sera (17–33 samples ⁄ age group).
Duplicate sera from individual patients were
avoided. Only patients with no indication of
febrile disease during the 2 weeks preceding
admission were admitted for elective surgery.
For blood donors, the required disease-free period
is at least 30 days.
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Eight different serological tests were evaluated:
Serodia-Myco II (Fujirebio, Tokyo, Japan), Lab-
systems M. pneumoniae IgM and IgG EIA (Ani
Labsystems, Helsinki, Finland), M. pneumoniae
IgM and IgG LISA tests (BMD SA, Marne La
Vallee, France), ImmunoWell M. pneumoniae test
(GenBio, RUST, Germany; this kit uses the same
materials as the LISA kit, but applies lower cut-
offs for adults), and SeroMP IgM and IgG tests
(Savyon Diagnostics, Ashdod, Israel). All tests
were performed and interpreted according to the
manufacturers’ instructions, and were reported as
negative, equivocal or positive. Statistical analysis
was with SPSS software v.12.0.0 (SPSS Inc.,
Chicago, IL, USA). Cohen’s kappa test was used
for comparing agreement between tests. The chi-
square test or Fisher’s exact test, as appropriate,
were used to analyse differences in proportions,
with p < 0.05 considered signiﬁcant.
The numbers of positive, equivocal and negat-
ive results varied among the different tests as
follows: Serodia-Myco II, 32, 26 and 146; Labsys-
tems M. pneumoniae IgM, 54, 60 and 90; Labsys-
tems M. pneumoniae IgG, 173, 14 and 17;
M. pneumoniae LISA IgM, 40, 9 and 155; M. pneu-
moniae LISA IgG, 34, 54 and 116; ImmunoWell IgG,
115, 47 and 42; SeroMP IgM, 16, 21 and 167; and
SeroMP IgG, 108, 19 and 77. Age had a major
inﬂuence on the proportion of positive sera
(Fig. 1). All kits showed peaks of positive IgM
tests for the 6–26-year age group in at least 20% of
sera. IgG levels increased with age, and remained
high even in the elderly. The decline in the number
of positive results with the LISA IgG assay for
adults reﬂects the higher cut-off point for this kit.
Inter-test agreement was very poor (Table 1).
The highest kappa value was c. 0.6 for the SeroMP
assay and the ImmunoWell IgG. Most other values
were well below that, even for the same immuno-
globulin. Positive or equivocal results were gen-
erally not associated with blood type, Rhesus
factor type, Coombs reaction or gender origin of
the sera tested, except that the Serodia kit tended
to give equivocal or positive results with Coombs-
positive sera (8 ⁄ 12, p 0.005). Unequivocal positiv-
ity also correlated with a positive Coombs reaction
(5 ⁄ 12, p 0.011) for this kit. The same tendency was
observed with the LISA IgGwith Coombs-positive
sera (9 ⁄ 12, p 0.033 for non-negative test results;
5 ⁄ 12, p 0.017 for clearly positive results). With the
LISA IgG assay there was also a signiﬁcant
association between blood group B and positive
or equivocal sera (63.4% of group B sera vs. 38.0%
of other groups; p < 0.003). This association was
also signiﬁcant for unequivocally positive sera
(26.8% of B group sera vs. 16.1% of other groups;
p < 0.029). While this suggested that blood group
B might produce some false-positive reactions
with this kit, another explanation might be the cut-
off calculation applied in this test, since the same
association was not observed with the Immuno-
Well IgG assay, which uses the same plates and
reagents. Interestingly, the LISA IgM and Labsys-
tems IgM gave more positive results with females
than with males (27.3% vs. 14.2%, p 0.021, and
34.8% vs. 20.4%, p 0.021, respectively).
The study showed that age was associated with
test positivity in healthy individuals, with the IgM
peaking at primary ⁄ secondary school age, and
declining thereafter. The high IgM positivity in
these age groups casts doubt on the suggestion
that combining IgM tests with ampliﬁcation-
based tests in the paediatric population might be
of beneﬁt [12–14]. Moreover, elevated IgM does
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Fig. 1. Distribution of positive results according to the
different assays tested: IgM and IgM-like assays (Serodia)
and IgG assays.
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not necessarily reﬂect recent exposure, since the
period from any disease to serum sampling was
at least 30 days for most samples. IgG positivity
persists into adulthood, with a small decline in
the elderly. Preliminary results from a new test
[15] suggest lower rates of positive results among
blood bank donors (2–4% IgM and 40–50% IgG),
but age distributions were not reported. Previous
suggestions [8,16] that positive results are more
prevalent in adults led [8] to the age-related
change of cut-off values in the LISA M. pneumo-
niae IgG assay, although this change was not
implemented in the ImmunoWell IgG assay,
which uses the same materials. The present data
suggest that such cut-off adjustments might not
sufﬁce. Poor agreement among different assays
has also been noted previously [6–9,11], and the
low kappa values suggest that some tests will give
misleading results.
As in other countries [16,17], the main exposure
to M. pneumoniae in the Israeli population occurs
during school age, resulting in at least 80% of
adults having antibodies (Fig. 1). Nevertheless,
there is an intriguing 6-year interval during which
the IgG peak lags behind the increase in IgM
levels. This might reﬂect the need for exposure to
more than one subtype to produce a sufﬁcient
immune response, or for multiple exposures to
the same pathogen. Overall, this study empha-
sises the need to use paired sera for the diagnosis
of M. pneumoniae infections, as well as the need
for more accurate and reliable diagnostic kits.
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Table 1. Agreement of performance among different tests according to Cohen’s kappa test
(a) According to positive, equivocal and negative results
Labsystems
IgM
Labsystems
IgG
LISA
IgM
LISA
IgG
ImmunoWell
IgG
SeroMP
IgM
SeroMP
IgG
Serodia 0.303a 0.030b 0.287a 0.173a 0.119a 0.381a 0.120c
Labsystems IgM 0.079c 0.288a 0.187a 0.200a 0.190a 0.168a
Labsystems IgG 0.023b 0.030b 0.228a 0.024b 0.217a
LISA IgM 0.091d 0.113a 0.377a 0.094d
LISA IgG 0.280a 0.140c 0.184a
ImmunoWell IgG 0.063d 0.455a
SeroMP IgM 0.105c
(b) According to negative and non-negative (positive + equivocal) results
Labsystems
IgM
Labsystems
IgG
LISA
IgM
LISA
IgG
ImmunoWell
IgG
SeroMP
IgM
SeroMP
IgG
Serodia 0.278a 0.055d 0.380a 0.229a 0.171a 0.499a 0.229a
Labsystems IgM 0.141a 0.361a 0.247a 0.242a 0.278a 0.263a
Labsystems IgG 0.029b 0.076d 0.288a 0.027b 0.211a
LISA IgM 0.122b 0.123a 0.451a 0.080b
LISA IgG 0.229a 0.198a 0.308a
ImmunoWell IgG 0.109a 0.553a
SeroMP IgM 0.137c
(c) According to positive-only results
Labsystems
IgM
Labsystems
IgG
LISA
IgM
LISA
IgG
ImmunoWell
IgG
SeroMP
IgM
SeroMP
IgG
Serodia 0.450a 0.038b 0.293a 0.277a 0.144c 0.349a 0.095b
Labsystems IgM 0.047b 0.450a 0.229a 0.269a 0.285a 0.141d
Labsystems IgG 0.029b 0.042b 0.311a 0.030b 0.315a
LISA IgM 0.109b 0.175a 0.396a 0.090b
LISA IgG 0.268a 0.060b 0.189a
ImmunoWell IgG 0.088c 0.595a
SeroMP IgM 0.066b
a p £ 0.001.
bp > 0.05, not signiﬁcant.
c0.001 < p £ 0.01.
d0.01 < p £ 0.05.
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ABSTRACT
In order to explore the genetic relationships
among coxsackie virus B5 strains in Greece, the
nucleotide sequences of the partial VP1 gene in
strains isolated from aseptic cases of meningitis
were determined and compared with those of
strains isolated from other countries. Phylogenet-
ic analysis showed a high degree of divergence
(25%) among Greek strains isolated in different
years, which clustered with high bootstrap val-
ues in a different subgroup of viruses, suggest-
ing that enterovirus types vary with time rather
than geographical distribution. A non-synony-
mous mutation present in the strains of this
study was not observed in other coxsackie virus
B5 strains.
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